Showing results (321-330 of 606) with videos related to

Sort By:
Pageof 61
Pharmacoeconomics - Open|January 27, 2019
Economic Impact and Clinical Outcomes of Omalizumab Add-On Therapy for Patients with Severe Persistent Asthma: A Real-World StudyLuis Manuel Entrenas Costa, Francisco Casas-Maldonado, José Gregorio Soto Campos, et al.
Pharmacoeconomics - Open|February 7, 2020
Cost Effectiveness of Antenatal Lifestyle Interventions for Preventing Gestational Diabetes and Hypertensive Disease in PregnancyCate Bailey, Helen Skouteris, Cheryce L Harrison, et al.
Pharmacoeconomics - Open|February 27, 2020
A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD StudyFernando de Andrés-Nogales, Miguel Ángel Casado, José Luis Trillo, et al.
Pharmacoeconomics - Open|January 29, 2020
DyeVert™ PLUS EZ System for Preventing Contrast-Induced Acute Kidney Injury in Patients Undergoing Diagnostic Coronary Angiography and/or Percutaneous Coronary Intervention: A UK-Based Cost-Utility AnalysisMehdi Javanbakht, Mohsen Rezaei Hemami, Atefeh Mashayekhi, et al.
Pharmacoeconomics - Open|November 25, 2020
Cost of Revision Total Knee Replacement: A Protocol for Systematic Review and Meta-AnalysisCharles Ebuka Okafor, Son Nghiem, Christopher Vertullo, et al.
Pharmacoeconomics - Open|November 9, 2020
Minimally Invasive Sacroiliac Joint Fusion with Triangular Titanium Implants: Cost-Utility Analysis from NHS PerspectiveDeirdre B Blissett, Rob S Blissett, Matthew P Newton Ede, et al.
Pharmacoeconomics - Open|March 29, 2020
The Budget Impact of Introducing Tildrakizumab to a United States Health Plan for Managing Moderate-to-Severe Plaque PsoriasisJustin Carrico, Yang Zhao, Xiaoying Jia, et al.
Pharmacoeconomics - Open|November 29, 2019
Cost-Effectiveness of Sertraline in Primary Care According to Initial Severity and Duration of Depressive Symptoms: Findings from the PANDA RCTWilliam Hollingworth, Christopher G Fawsitt, Padraig Dixon, et al.
Pharmacoeconomics - Open|March 15, 2018
Functional Status and Well-Being in People with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Compared with People with Multiple Sclerosis and Healthy ControlsCaroline C Kingdon, Erinna W Bowman, Hayley Curran, et al.
Pharmacoeconomics - Open|November 10, 2021
Examining Ways to Improve Weight Control Programs' Population Reach and Representativeness: A Discrete Choice Experiment of Financial IncentivesWen You, Yuan Yuan, Kevin J Boyle, et al.
Pageof 61